Spinal Muscular Atrophy Clinical Trial
Official title:
SMN Copy Number Distribution in Mali, West Africa
Background:
- Spinal muscular atrophy (SMA) is a degenerative and incurable neuromuscular disorder
that is caused by mutations in the survival motor neuron gene, SMN1, found on chromosome
5. It is the leading inherited cause of infant mortality. SMA carriers (those who have
the genetic mutation but do not have the disease) are often unaware of their status
until they are tested.
- Researchers have been studying the prevalence of SMA carriers in the general population,
but most of the information collected has come from populations within the United
States, Europe, and Asia. Very few studies have been performed in Africa. Furthermore,
this information does not provide much information regarding carrier frequency based on
ethnic background and ancestry. To address this problem, researchers are interested in
studying the prevalence of the SMA genetic mutation in the sub-Saharan nation of Mali.
Objectives:
- To collect blood samples for use in studying genetic data related to spinal muscular
atrophy.
Eligibility:
- Healthy volunteers who are at least 18 years of age.
- Volunteers will be of Malian ancestry and nationality.
Study Location:
-<TAB>Bamako, Mali, West Africa
Design:
- The study will first collect blood samples from a small group of volunteers to run
initial SMA carrier testing and resolve any technical difficulties before continuing
with the study.
- Participants will complete questionnaires about their personal and family medical
history, including questions about illnesses, stillborns, and miscarriages, and then
will provide blood samples for genetic research and testing.
Objective
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease that is caused
by mutations in the survival motor neuron gene, SMN1. The objective of this study is to
determine the SMN copy number distribution in the Malian population and to compare this to
published data obtained elsewhere. It is anticipated that this study will help to refine the
knowledge of SMA by assessing the distribution of SMN copy number, and the SMA carrier
frequency in a sub-Saharan nation, thus expanding the information base available to
clinicians and patients considering SMA carrier testing.
Study Population
The study population will include 1400 adult (18 years of age and older) volunteers only.
Design
Blood samples from volunteers will be collected from students at the School of Medicine,
Pharmacy, and Dentistry (FMPOS) at the University of Bamako, which consists of an ethnically
diverse population representative of the Malian ethnicities. No therapy will be provided to
study participants.
Outcome Measures
Outcome measure for phase 1 is DNA extraction yield of sufficient quantity and quality for
SMN genotyping by LabCorp in at least 90% of samples. Outcome measures for phase 2 are the
frequency of SMA carriers (SMN1 deletion heterozygotes) and the SMN1 and SMN2 copy number
distribution in Mali.
Abbreviations and Definition of Terms
- SMA: Spinal Muscular Atrophy
- SMN: Survival Motor Neuron
- SMN1: Survival Motor Neuron Telomeric
- SMN2: Survival Motor Neuron Centromeric
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|